Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1

Journal of Medicinal Chemistry

Volumn 51, Issue 9, 2008, Pages 2638-2647

  Gopi, Hosahudya ^a   Umashankara, M ^a   Pirrone, Vanessa ^a   LaLonde, Judith ^b   Madani, Navid ^c   Tuzer, Ferit ^a   Baxter, Sabine ^a   Zentner, Isaac ^a   Cocklin, Simon ^a   Jawanda, Navneet ^a   Miller, Shendra R ^a   Schön, Arne ^d   Klein, Jeffrey C ^d   Freire, Ernesto ^d   Krebs, Fred C ^a   Smith, Amos B ^e   Sodroski, Joseph ^c   Chaiken, Irwin ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BRYN MAWR COLLEGE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLENE DERIVATIVE; ANTIVIRUS AGENT; GLYCOPROTEIN GP 120; PROLINE DERIVATIVE; TRIAZOLE; VIRUS RECEPTOR;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CELL ASSAY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; MOLECULAR WEIGHT; NONHUMAN; REACTION ANALYSIS; RECEPTOR AFFINITY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; BINDING SITES; CELL LINE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MOLECULAR MIMICRY; PEPTIDES; PROTEIN BINDING; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 42949103034     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070814r     Document Type: Article

References (51)

1. AIDS Epidemic Update; WHO/UNAIDS, December, 2005.
2. Klatzmann, D.; Champagne, E.; Chamaret, S.; Gruest, J.; Guetard, D.; Hercend, T.; Gluckman, J. C.; Montagnier, L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312 (5996), 767-768.
3. Dalgleish, A. G.; Beverley, P. C.; Clapham, P. R.; Crawford, D. H.; Greaves, M. F.; Weiss, R. A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312 (5996), 763-767.
4. Chan, D. C.; Fass, D.; Berger, J. M.; Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89 (2), 263-273.
5. Wyatt, R.; Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280 (5371), 1884-1888.
6. Tan, K.; Liu, J.; Wang, J.; Shen, S.; Lu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (23), 12303-12308.
7. Kwong, P. D.; Wyatt, R.; Robinson, J.; Sweet, R. W.; Sodroski, J.; Hendrickson, W. A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393 (6686), 648-659.
8. Huang, C. C.; Stricher, F.; Martin, L.; Decker, J. M.; Majeed, S.; Barthe, P.; Hendrickson, W. A.; Robinson, J.; Roumestand, C.; Sodroski, J.; Wyatt, R.; Shaw, G. M.; Vita, C.; Kwong, P. D. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure 2005, 13 (5), 755-768.
9. Huang, C. C.; Tang, M.; Zhang, M. Y.; Majeed, S.; Montabana, E.; Stanfield, R. L.; Dimitrov, D. S.; Korber, B.; Sodroski, J.; Wilson, I. A.; Wyatt, R.; Kwong, P. D. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310 (5750), 1025-1028.
10. Kwong, P. D.; Wyatt, R.; Majeed, S.; Robinson, J.; Sweet, R. W.; Sodroski, J.; Hendrickson, W. A. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000, 8 (12), 1329-1339.
11. Wu, L.; Gerard, N. P.; Wyatt, R.; Choe, H.; Parolin, C.; Ruffing, N.; Borsetti, A.; Cardoso, A. A.; Desjardin, E.; Newman, W.; Gerard, C.; Sodroski, J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384 (6605), 179-183.
12. Dragic, T.; Litwin, V.; Allaway, G. P.; Martin, S. R.; Huang, Y.; Nagashima, K. A.; Cayanan, C.; Maddon, P. J.; Koup, R. A.; Moore, J. P.; Paxton, W. A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381 (6584), 667-673.
13. Doranz, B. J.; Berson, J. F.; Rucker, J.; Doms, R. W. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol. Res. 1997, 16 (1), 15-28.
14. Moore, J. P.; Doms, R. W. The entry of entry inhibitors: a fusion of science and medicine. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (19), 10598-10602.
15. Tsibris, A. M.; Kuritzkes, D. R. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 2007, 58, 445-459.
16. Munk, C.; Wei, G.; Yang, O. O.; Waring, A. J.; Wang, W.; Hong, T.; Lehrer, R. I.; Landau, N. R.; Cole, A. M. The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res. Hum. Retroviruses 2003, 19 (10), 875-881.
17. Gallo, S. A.; Wang, W.; Rawat, S. S.; Jung, G.; Waring, A. J.; Cole, A. M.; Lu, H.; Yan, X.; Daly, N. L.; Craik, D. J.; Jiang, S.; Lehrer, R. I.; Blumenthal, R. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J. Biol. Chem. 2006, 281 (27), 18787-18792.
18. Zhang, M. Y.; Dimitrov, D. S. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr. Pharm. Des. 2007, 13 (2), 203-212.
19. Cardoso, R. M.; Zwick, M. B.; Stanfield, R. L.; Kunert, R.; Binley, J. M.; Katinger, H.; Burton, D. R.; Wilson, I. A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22 (2), 163-173.
20. Zhang, M. Y.; Shu, Y.; Phogat, S.; Xiao, X.; Cham, F.; Bouma, P.; Choudhary, A.; Feng, Y. R.; Sanz, I.; Rybak, S.; Broder, C. C.; Quinnan, G. V.; Evans, T.; Dimitrov, D. S. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J. Immunol. Methods 2003, 283 (1-2), 17-25.
21. Lin, P. F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.; Gong, Y. F.; Wang, H. G.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C. B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (19), 11013-11018.
22. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A. K. Identification of N-phenyl-N′- (2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005, 339 (2), 213-225.
23. Ferrer, M.; Harrison, S. C. Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J. Virol. 1999, 73 (7), 5795-5802.
24. Vita, C.; Drakopoulou, E.; Vizzavona, J.; Rochette, S.; Martin, L.; Menez, A.; Roumestand, C.; Yang, Y. S.; Ylisastigui, L.; Benjouad, A.; Gluckman, J. C. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (23), 13091-13096.
25. DeMarco, S. J.; Henze, H.; Lederer, A.; Moehle, K.; Mukherjee, R.; Romagnoli, B.; Robinson, J. A.; Brianza, F.; Gombert, F. O.; Lociuro, S.; Ludin, C.; Vrijbloed, J. W.; Zumbrunn, J.; Obrecht, J. P.; Obrecht, D.; Brondani, V.; Hamy, F.; Klimkait, T. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg. Med. Chem. 2006, 14 (24), 8396-8404.
26. Gopi, H. N.; Tirupula, K. C.; Baxter, S.; Ajith, S.; Chaiken, I. M. Click chemistry on azidoproline: high-affinity dual antagonist for HIV-1 envelope glycoprotein gp120. ChemMedChem 2006, 1 (1), 54-57.
27. Cocklin, S.; Gopi, H.; Querido, B.; Nimmagadda, M.; Kuriakose, S.; Cicala, C.; Ajith, S.; Baxter, S.; Arthos, J.; Martin-Garcia, J.; Chaiken, I. M. Broad-spectrum anti-HIV Potential of a Peptide HIV-1 Entry Inhibitor. J. Virol. 2007, 81 (7), 3645-3648.
28. Biorn, A. C.; Cocklin, S.; Madani, N.; Si, Z.; Ivanovic, T.; Samanen, J.; Van Ryk, D. I.; Pantophlet, R.; Burton, D. R.; Freire, E.; Sodroski, J.; Chaiken, I. M. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry 2004, 43 (7), 1928-1938.
29. Smith, A. B.; Savinov, S. N.; Manjappara, U. V.; Chaiken, I. M. Peptide-small molecule hybrids via orthogonal deprotection-chemoselective conjugation to cysteine-anchored scaffolds. A model study. Org. Lett. 2002, 4 (23), 4041-4044.
30. Leavitt, S. A.; Schön, A.; Klein, J. C.; Manjappara, U.; Chaiken, I. M.; Freire, E. Interactions of HIV-1 proteins gp120 and Nef with cellular partners define a novel allosteric paradigm. Curr. Protein. Pept. Sci. 2004, 5 (1), 1-8.
31. Schön, A.; Madani, N.; Klein, J. C.; Hubicki, A.; Ng, D.; Yang, X.; Smith, A. B.; Sodroski, J.; Freire, E. Thermodynamics of Binding of a Low-Molecular-Weight CD4 Mimetic to HIV-1 gp120. Biochemistry 2006, 45 (36), 10973-10980.
32. Wyatt, R.; Kwong, P. D.; Desjardins, E.; Sweet, R. W.; Robinson, J.; Hendrickson, W. A.; Sodroski, J. G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393 (6686), 705-711.
33. Xiang, S. H.; Kwong, P. D.; Gupta, R.; Rizzuto, C. D.; Casper, D. J.; Wyatt, R.; Wang, L.; Hendrickson, W. A.; Doyle, M. L.; Sodroski, J. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 2002, 76 (19), 9888-9899.
34. Rizzuto, C. D.; Wyatt, R.; Hernandez-Ramos, N.; Sun, Y.; Kwong, P. D.; Hendrickson, W. A.; Sodroski, J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280 (5371), 1949-1953.
35. Thali, M.; Moore, J. P.; Furman, C.; Charles, M.; Ho, D. D.; Robinson, J.; Sodroski, J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 1993, 67 (7), 3978-3988.
36. Xiang, S. H.; Wang, L.; Abreu, M.; Huang, C. C.; Kwong, P. D.; Rosenberg, E.; Robinson, J. E.; Sodroski, J. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology 2003, 315 (1), 124-134.
37. Parren, P. W.; Mondor, I.; Naniche, D.; Ditzel, H. J.; Klasse, P. J.; Burton, D. R.; Sattentau, Q. J. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J. Virol. 1998, 72 (5), 3512-3519.
38. Yang, X.; Lipchina, I.; Cocklin, S.; Chaiken, I.; Sodroski, J. Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization. J. Virol. 2006, 80 (22), 11404-11408.
39. Link, A. J.; Vink, M. K.; Tirrell, D. A. Presentation and detection of azide functionality in bacterial cell surface proteins. J. Am. Chem. Soc. 2004, 126 (34), 10598-10602.
40. Culp, J. S.; Johansen, H.; Hellmig, B.; Beck, J.; Matthews, T. J.; Delers, A.; Rosenberg, M. Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells. Biotechnology (NY) 1991, 9 (2), 173-177.
41. Gopi, H. N.; Tirupula, K. C.; Baxter, S.; Ajith, S.; Chaiken, I. M. Click Chemistry on Azidoproline: High-Affinity Dual Antagonist for HIV-1 Envelope Glycoprotein gp120. ChemMedChem 2006, 1 (1), 54-57.
42. Ishino, T.; Pillalamarri, U.; Panarello, D.; Bhattacharya, M.; Urbina, C.; Horvat, S.; Sarkhel, S.; Jameson, B.; Chaiken, I. Asymmetric usage of antagonist charged residues drives interleukin-5 receptor recruitment but is insufficient for receptor activation. Biochemistry 2006, 45 (4), 1106-1115.
43. Charneau, P.; Mirambeau, G.; Roux, P.; Paulous, S.; Buc, H.; Clavel, F. HIV-1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol. 1994, 241 (5), 651-662.
44. Gartner, S.; Markovits, P.; Markovitz, D. M.; Kaplan, M. H.; Gallo, R. C.; Popovic, M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986, 233 (4760), 215-219.
45. Popovic, M.; Gartner, S. Biology of human imunodeficiency virus: virus receptor and cell tropism. Curr. Opin. Immunol. 1989, 1 (3), 516-520.
46. Krebs, F. C.; Miller, S. R.; Malamud, D.; Howett, M. K.; Wigdahl, B. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res. 1999, 43 (3), 157-173.
47. Parolin, C.; Taddeo, B.; Palu, G.; Sodroski, J. Use of cis- and trans-acting viral regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes. Virology 1996, 222 (2), 415-422.
48. Rho, H. M.; Poiesz, B.; Ruscetti, F. W.; Gallo, R. C. Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology 1981, 112 (1), 355-360.
49. MOE Molecular Operating Environment Chemical Computing Group, http//www.chemcomp.com/, Montreal, Canada.
50. Halgren, T. A. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 1999, 20, 720-729.
51. Halgren, T. A. MMFF MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comput. Chem. 1999, 20, 740-774.